Diclofenac

## Report on Diclofenac Injection Package Insert Amendment **1. Executive Summary:** This report analyzes a directive from the Central Drugs Standard Control Organization (CDSCO) regarding Diclofenac injection. The directive mandates the inclusion of Nicolaus Syndrome as an adverse drug reaction (ADR) in the package insert and promotional literature for Diclofenac injection marketed in India. This change is based on recommendations from the Pharmacovigilance Programme of India (PvPI) and subsequent deliberation by a Subject Expert Committee. The core purpose is to enhance patient safety by providing more comprehensive information about potential risks associated with the drug. **2. Introduction:** This report aims to provide an informative overview of a directive issued by the CDSCO concerning the prescribing information for Diclofenac injection, based solely on the provided document. The report outlines the background, key changes mandated, affected parties, and potential impact of this regulatory update. **3. Policy Overview:** * This directive constitutes an *amendment* to the existing regulatory framework governing the labeling and marketing of Diclofenac injection in India. * **Core Objective(s):** Based on the text, the primary objective is to enhance patient safety by ensuring that healthcare professionals and patients are informed about the potential risk of Nicolaus Syndrome associated with Diclofenac injection. **4. Background and Rationale:** * This amendment addresses the need to update the prescribing information for Diclofenac injection to include Nicolaus Syndrome as a known adverse drug reaction. The rationale stems from ADR reports analyzed by the National Coordination Centre for Pharmacovigilance Programme of India (NCCPvPI), indicating a potential link between Diclofenac and the occurrence of Nicolaus Syndrome. The amendment aims to ensure accurate and comprehensive risk communication. **5. Key Provisions / Changes:** * The amendment *specifically* focuses on updating the package insert/promotional material of Diclofenac injection. * The *new* rule/provision requires manufacturers of Diclofenac injection to include Nicolaus Syndrome as an adverse drug reaction in the package insert and promotional literature. * The *effect* of this change is to provide healthcare professionals and patients with more complete information about the potential risks associated with the drug. This allows for better informed decisions regarding treatment options and potentially reduces the risk of misdiagnosis or delayed intervention in cases of Nicolaus Syndrome. **6. Target Audience and Stakeholders:** The primary target audience and stakeholders directly affected by this amendment are: * Manufacturers of Diclofenac injection in India. * State/UT Drugs Controllers who regulate these manufacturers. * Healthcare professionals prescribing Diclofenac injection. * Patients receiving Diclofenac injection. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The CDSCO is the primary responsible agency. The State/UT Drugs Controllers are responsible for directing manufacturers within their jurisdiction. The PvPI plays an advisory role. * **Timelines/Procedures:** The text requests State/UT Drugs Controllers to direct manufacturers to update their package inserts and promotional materials. It also requests that action taken be reported back to the CDSCO. Specific timelines for implementation are not provided within this document. * This amendment focuses implementation on the manufacturers' updates to product labeling and promotional materials. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of this amendment is improved patient safety through: * Increased awareness among healthcare professionals about the potential association between Diclofenac injection and Nicolaus Syndrome. * Better-informed prescribing decisions by healthcare professionals. * Increased vigilance among patients and healthcare professionals for the signs and symptoms of Nicolaus Syndrome in patients receiving Diclofenac injection. * Potentially earlier diagnosis and management of Nicolaus Syndrome in affected individuals. **9. Conclusion:** The CDSCO directive mandating the inclusion of Nicolaus Syndrome as an ADR in the package insert for Diclofenac injection represents a significant step towards enhancing patient safety. By ensuring that healthcare professionals and patients have access to comprehensive information about the potential risks associated with the drug, this amendment is likely to contribute to more informed decision-making and potentially improve outcomes for individuals receiving Diclofenac injection. The directive's success hinges on the prompt and effective implementation by manufacturers and the diligent enforcement by regulatory bodies.

Key Entities Referenced